does anyone know any of the specifics of the additional test management mentioned they are going to embark on? who is going to administer? date it will start / end? number of patients? end goal?
i am assuming they are simply trying to enhance their previous results and add one more piece of scientific data (unlike purdue) for the advisory panel to evaluate. this is only a guess, but i am assuming the real issue is the niacin aspect.
any thoughts as to what the value would be if they didn't get the verbage on the labeling and had to go the generic route? i know there have been all kinds of proforma's, but i don't recall anything dealing with the generic branding.....